Comparative Analysis of Peptide Composition and Bioactivity of Different Collagen Hydrolysate Batches on Human Osteoarthritic Synoviocytes

Simons VS, Lochnit G, Wilhelm J, Ishaque B, Rickert M, Steinmeyer J · Scientific Reports

Two uncomfortable findings at once. Peptide composition differed markedly between preparations AND between production batches of the same preparation — there is no standardisation behind the label. And no significant effect on cultured synoviocytes could be demonstrated for any batch of any of the three products across the targets examined.

Population

Human osteoarthritic fibroblast-like synoviocytes; three commercial collagen hydrolysates (CH-Alpha, Peptan B 2000, Mobiforte) and multiple production batches of each

Intervention

MALDI-TOF and ICPL isotope-labelling composition analysis, plus pharmacological testing on synoviocytes

Limitations

In-vitro only, and the authors note they examined a small number of pharmacologically relevant targets, so absence of effect here is not proof of inertness in vivo. Independent (Justus Liebig University Giessen), no competing interests declared.